Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: Does bulking substance matter?

Doğan, Hasan Serkan; Altan, Mesut; Çıtamak, Burak; Bozacı, Ali Cansu; Koni, Artan; Tekgül, Serdar

doi:10.1016/j.jpurol.2014.12.009

Cited by 27 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it should be highlighted that appropriate selection of the patients to undergo endoscopic correction of the VUR, not only enhances procedure success rate, but also may provide better symptoms resolution. Various preoperative factors including younger age before treatment and previous history of the failed endoscopic injection may be related to the intervention failure, which was detected by Serkan et al (25). On the other hand, some other studies suggested that preoperative history of dysfunctions and neurogenic disorders have a role in the failure of VUR endoscopic treatment (30)(31)(32).…”

Section: Discussionmentioning

confidence: 94%

“…Although the success rate for endoscopic interventions in VUR treatment varies between 70% and 90% in the literature, the optimal technique and bulking agent for STING are controversial (23,24). In addition, it is believed that the advantages of endoscopic intervention provide a possibility to repeat the procedure in case of failure or recurrence (25). For the first time, Matouschek used Teflon particles for injection (12).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, it has been reported to be durable, but some studies suggested that its biodegradability leads to lower durability and VUR recurrence following degradation (27,28). Although many studies suggest that appropriate selection of patients can lead to higher success rate, lower recurrence and complications, however biodegradable agents such as Dx/HA may cause VUR recurrence and failure during long-term follow up (25). The reported success rate is 70% for VUR correction using STING procedure in the literature (8,23).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Endoscopic correction of vesicoureteral reflux in children

Rahimi¹,

Nazarbaghi²,

Valizadeh³

et al. 2018

J Renal Inj Prev

View full text Add to dashboard Cite

Implication for health policy/practice/research/medical education:Dextranomer/hyaluronic acid subureteric injection provides acceptable resolution rate among vesicoureteral reflux (VUR) patients and this highlights the necessity for the strict implementation of it in VUR. Additionally patients underwent a one-year follow up period, subsequently. Follow up included urine analysis, urine cultures and kidney and urinary tract ultrasonography study. Results: Of a total 30 patients, 8 patients (27%) were male and 22 patients (73%) were female. The mean age of patients was 25.19 ± 0.70 months. Postoperative VUR resolution was observed in 28 patients (93.3%). Moreover, during one year follow up, urinary tract infection (UTI) was not reported in patients. However, recurrent VUR was detected in 8 patients (27%) during ultrasonography follow up. Analysis showed no significant difference of recurrence in VUR between males and females (P = 0.285) and VUR severity (P = 0.1). There was a significant relationship between recurrent UTI history before intervention and VUR recurrence after subureteric injection (P = 0.007). Conclusion: Dx/HA acid subureteric injection provides acceptable resolution rate among VUR patients, but its biodegradability causes VUR recurrence during one-year follow up. Please cite this paper as:

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endoscopic correction of vesicoureteral reflux in children

Rahimi¹,

Nazarbaghi²,

Valizadeh³

et al. 2018

J Renal Inj Prev

View full text Add to dashboard Cite

show abstract

“…Recently a similar compound (Dexell) has been produced, which is biochemically similar to Deflux with a different molecular size. Two articles documented the use of Dexell with comparable results with Deflux, indicating the indifference of their molecular sizes in the success rate of ET (16,17).…”

Section: Discussionmentioning

confidence: 99%

“…Deflux has dextranomer microspheres ranging in size from 80 to 250 microns (an average size of 130 microns) while the size of Dexell dextranomer microsphere is 80 to 120 microns. Therapeutically, no significant difference in the outcome of these two agents has been found (16,17). The ideal injectable bulking agent should be durable, effective, safe, stable, none migrating, biocompatible, noneantigenic, and none-carcinogenic (18,19).…”

Section: Introductionmentioning

confidence: 99%

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Jaafar

Hussein

2016

Int J Infect

View full text Add to dashboard Cite

Background: Recurrent urinary tract infection (UTI) due to vesicoureteral reflux (VUR) is common in Iraq. Endoscopic treatment of VUR is used with advantages over antibiotic prophylaxis and ureteral reimplantation. Objectives: This study was performed to assess the efficacy of a new agent, Dexell, for treating patients with VUR and its ability to manage recurrent UTI. Materials and Methods:This research was a prospective study recruiting 156 patients with VUR treated by endoscopic subureteric injection of Dexell. Results: VUR were unilateral in 87 cases and bilateral in 69 cases. VUR grades II-V were 18.7%, 28%, 32%, and 21.3%, respectively. The success rates were 64% after the first injection, 82.7% after second injection, and 93.3% after third injection. All patients with grades II and III were resolved completely while the success rates in higher grades were 91.7% for grade IV and 87.5% for grade V. No significant difference was noted between males and females regarding the success rate of endoscopic treatment (92% vs 91.6%, P > 0.05). Recurrent UTI did not occur throughout the study period after the operation. Conclusions: Cystoscopic injection of Dexell is an effective method for treating patients with VUR. It is a safe day case procedure that can prevent recurrent UTI in patients with VUR.

show abstract

Robot-assisted extravesical ureteral reimplantation (revur) for unilateral vesico-ureteral reflux in children: results of a multicentric international survey

et al. 2017

View full text Add to dashboard Cite

REVUR is a safe and effective technique for treatment of primary unilateral VUR. The procedure is easy and fast to perform thanks to the 6° of freedom of robotic arms. The learning curve is short and it is useful to begin the robotics experience with a surgeon expert in robotic surgery as proctor on the 2nd robot console. The high cost and the diameter of instruments remain the main challenges of robotics applications in pediatric urology.

show abstract

Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: Does bulking substance matter?

Cited by 27 publications

References 19 publications

Endoscopic correction of vesicoureteral reflux in children

Endoscopic correction of vesicoureteral reflux in children

Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

Robot-assisted extravesical ureteral reimplantation (revur) for unilateral vesico-ureteral reflux in children: results of a multicentric international survey

Contact Info

Product

Resources

About